Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
6 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Enliven Therapeutics, Inc.’s names, not what it holds today.
Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 3 in 2023
Applications published
21
2 of them in 2025
Names they are printed under
6
a former name, its own name, a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
Imara Inc. a former name
named as the applicant on its applications, in US
8 publishedEnLiven Therapeutics, Inc. its own name
named as the applicant on its applications, in US
7 publishedEnliven Inc. a subsidiary
US, as the owner printed on each patent
1 publishedEnliven Inc. a subsidiary
named as the applicant on its applications, in US
5 publishedEnLiven Therapeutics, Inc. its own name
US, as the owner printed on each patent
0 publishedImara Inc. a former name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 4, 2025 | 12,240,846 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | Pharmaceuticals | Enliven Inc. |
| Nov 7, 2023 | 11,807,649 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | Organic fine chemistry | EnLiven Therapeutics, Inc. |
| Nov 7, 2023 | 11,807,638 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | Pharmaceuticals | Enliven Inc. |
| Sep 26, 2023 | 11,767,321 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | Pharmaceuticals | Enliven Inc. |
| Jun 28, 2022 | 11,370,795 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | Pharmaceuticals | Imara Inc. |
| May 21, 2002 | 6,393,407 | Tracking user micro-interactions with web page advertising | IT methods for management | Enliven Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 24, 2025 | 2025/0236621 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Pharmaceuticals | Enliven Inc. |
| May 1, 2025 | 2025/0136595 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Organic fine chemistry | Enliven Inc. |
| Aug 29, 2024 | 2024/0287062 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | Pharmaceuticals | Enliven Inc. |
| Jul 11, 2024 | 2024/0228486 | SULFONE- AND SULFOXIMINE-BASED SELECTIVE PARP1 INHIBITORS | Organic fine chemistry | Enliven Inc. |
| Apr 11, 2024 | 2024/0116921 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Organic fine chemistry | EnLiven Therapeutics, Inc. |
| Feb 8, 2024 | 2024/0043420 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Organic fine chemistry | EnLiven Therapeutics, Inc. |
| Nov 30, 2023 | 2023/0382923 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Organic fine chemistry | EnLiven Therapeutics, Inc. |
| Nov 30, 2023 | 2023/0382907 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Pharmaceuticals | Enliven Inc. · patent 12,240,846 granted from it |
| Aug 24, 2023 | 2023/0265098 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Organic fine chemistry | EnLiven Therapeutics, Inc. |
| May 25, 2023 | 2023/0159557 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Organic fine chemistry | EnLiven Therapeutics, Inc. · patent 11,807,649 granted from it |
What it applied for, 2024 to 2025: Organic fine chemistry 4 · Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.